The FDA has approved the immunotherapy drug nivolumab (Opdivo) for patients with metastatic colorectal cancer that has one of two specific genetic features, high microsatellite instability (MSI-H) and mismatch repair deficiency (dMMR). These genetic features are hallmarks of most Lynch Syndrome tumors.
Learn more:
https://www.cancer.gov/news-events/cancer-currents-blog/2017/nivolumab-fda-colorectal